8-K: NextCure Faces Nasdaq Delisting Threat After Share Price Drops Below $1.00

NextCure, Inc. received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement, potentially leading to delisting.

Summary

• NextCure, Inc. received a notification from Nasdaq on January 31, 2025, indicating that its common stock's closing price had fallen below the required $1.00 per share minimum for 30 consecutive business days.
• This violates Nasdaq Listing Rule 5450(a)(1), which mandates a minimum average closing price to maintain listing on the Nasdaq Global Select Market.
• NextCure has been granted a grace period until July 30, 2025, to regain compliance by maintaining a share price of at least $1.00 for a minimum of ten consecutive business days.
• The company may be eligible for an additional 180-day extension if it meets other Nasdaq listing standards and provides written notice of its intent to cure the deficiency, potentially through a reverse stock split.
• Failure to regain compliance could result in Nasdaq delisting NextCure's common stock, although the company would have the right to appeal this decision.
• NextCure intends to monitor its stock price and consider options, including a reverse stock split, to regain compliance, but there is no guarantee of success.

Sentiment

Score: 3

Explanation: The sentiment is negative due to the delisting notice and uncertainty surrounding the company's ability to regain compliance with Nasdaq listing requirements.

Positives

• NextCure has a grace period until July 30, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
• The company may be eligible for an additional 180-day extension to regain compliance.
• NextCure has the option to appeal a delisting determination to a Nasdaq Listing Qualifications Panel.

Negatives

• NextCure's stock price has fallen below $1.00 for 30 consecutive business days, triggering a delisting warning from Nasdaq.
• There is no guarantee that NextCure will be able to regain compliance with the minimum bid price requirement.
• Delisting from the Nasdaq Global Select Market could negatively impact investor confidence and the company's ability to raise capital.

Risks

• Failure to regain compliance with Nasdaq listing requirements could lead to delisting.
• A reverse stock split, while potentially increasing the share price, could be viewed negatively by investors.
• There is no assurance that NextCure will be able to maintain compliance with other Nasdaq listing requirements.

Future Outlook

NextCure intends to actively monitor its stock price and evaluate available options, including a reverse stock split, to regain compliance with the Minimum Bid Requirement, but there is no assurance of success.

Industry Context

Delisting notices are not uncommon for biotech companies, especially those in the clinical stage, as their stock prices can be volatile and heavily dependent on clinical trial results and regulatory approvals. Many companies in similar situations consider reverse stock splits to artificially inflate their share price to meet listing requirements.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with maintaining Nasdaq listing compliance.
• Reverse stock splits are a common, though often unpopular, method employed by companies like NextCure to artificially inflate their share price.
• Companies such as Geron Corporation and Ocugen Inc. have previously faced similar delisting warnings and implemented reverse stock splits to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment if the company is delisted.
• Employees may face uncertainty regarding their job security if the company's financial situation deteriorates.
• The company's ability to raise capital may be negatively impacted if it is delisted.

Next Steps

• NextCure will actively monitor the closing bid price of its common stock.
• NextCure will evaluate available options to regain compliance with the Minimum Bid Requirement, which may include a reverse stock split.

Key Dates